The DOI matches its Crossref record; 784 of the 784 references it cites were found in a registry or an index.
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Open accessAbstract
Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite the established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, and the exploration of emerging modalities such as immunotherapy and integration of medicine and engineering technology therapy, the efficacy of these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny of the inhibitory and immunosuppressive milieu within GBM has underscored the significance of cellular constituents of the GBM microenvironment and their interactions with malignant cells and neurons. Novel immune and targeted therapy strategies have emerged, offering promising avenues for advancing GBM treatment. One pivotal mechanism orchestrating immunosuppression in GBM involves the aggregation of myeloid-derived suppressor cells (MDSCs), glioma-associated macrophage/microglia (GAM), and regulatory T cells (Tregs). Among these, MDSCs, though constituting a minority (4–8%) of CD45+ cells in GBM, play a central component in fostering immune evasion and propelling tumor progression, angiogenesis, invasion, and metastasis. MDSCs deploy intricate immunosuppressive mechanisms that adapt to the dynamic tumor microenvironment (TME). Understanding the interplay between GBM and MDSCs provides a compelling basis for therapeutic interventions. This review seeks to elucidate the immune regulatory mechanisms inherent in the GBM microenvironment, explore existing therapeutic targets, and consolidate recent insights into MDSC induction and their contribution to GBM immunosuppression. Additionally, the review comprehensively surveys ongoing clinical trials and potential treatment strategies, envisioning a future where targeting MDSCs could reshape the immune landscape of GBM. Through the synergistic integration of immunotherapy with other therapeutic modalities, this approach can establish a multidisciplinary, multi-target paradigm, ultimately improving the prognosis and quality of life in patients with GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–784 of 784
Kinoshita, R., Sato, H., 山内, 明., Takahashi, Y., Inoue, Y., Sumardika, I. W., Chen, Y., Tomonobu, N., Araki, K., Shien, K., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31982 · Cited by 62
Shen, C., Huang, B., Yeh, W., Chen, C., Liu, Y.-S., Lai, S., Tseng, W., Lu, D., & Tsai, C. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174216 · Cited by 62
Otani, Y., Yoo, J. Y., Lewis, C. T., Chao, S., Swanner, J. L., Shimizu, T., Kang, J. M., Murphy, S. A., Rivera-Caraballo, K., Hong, B., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2347 · Cited by 62
Transcription factors in myeloid-derived suppressor cell recruitment and function
Sonda, N., Chioda, M., Zilio, S., Simonato, F., & Bronte, V. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.006 · Cited by 61
Xu, P., Yin, K., Tang, X., Tian, J., Zhang, Y., Ma, J., Xu, H., Xu, Q., & Wang, S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109458 · Cited by 61
Nigam, S., McCarl, L. H., Kumar, R., Edinger, R. S., Kurland, B. F., Anderson, C. J., Panigrahy, A., Kohanbash, G., & Edwards, W. B. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01427-1 · Cited by 61
Cancer cell intrinsic TIM-3 induces glioblastoma progression
Guo, Q., Shen, S., Guan, G., Zhu, C. Y., Zou, C., Cao, J., Cheng, W., Xu, X., Yu, J., Lin, Z., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105329 · Cited by 60
Baron, J. M., Boster, B. L., & Barnett, C. M. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214527144 · Cited by 59
Choi, S. H., Stuckey, D. W., Pignatta, S., Reinshagen, C., Khalsa, J. K., Roozendaal, N., Martínez‐Quintanilla, J., Tamura, K., Keleş, E., & Shah, K. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0077 · Cited by 59
Yoon, S., Wu, X., Armstrong, B., Habib, N., & Rossi, J. J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.012 · Cited by 59
Ohno, M., Matsuzaki, J., Kawauchi, J., Aoki, Y., Miura, J., Takizawa, S., Kato, K., Sakamoto, H., Matsushita, Y., Takahashi, M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16953 · Cited by 59
Dejaegher, J., Solie, L., Hunin, Z., Sciot, R., Capper, D., Siewert, C., Cauter, S. V., Wilms, G., van Loon, J., Ectors, N., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa247 · Cited by 59
Penfluridol suppresses glioblastoma tumor growth by Akt-mediated inhibition of GLI1
Ranjan, A., & Srivastava, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16515 · Cited by 58
Magod, P., Mastandrea, I., Rousso-Noori, L., Agemy, L., Shapira, G., Shomron, N., & Friedmann‐Morvinski, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109480 · Cited by 58
Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas
Choi, S. H., Tamura, K., Khajuria, R. K., Bhere, D., Nesterenko, I., Lawler, J., & Shah, K. (2014) · Molecular Therapy · doi:10.1038/mt.2014.214 · Cited by 57
Metabolic regulation on the immune environment of glioma through gut microbiota
Lyu, Y., Yang, H., & Liang, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.005 · Cited by 57
Self-citationParik, S., Fernández-García, J., Lodi, F., Vlaminck, K. D., Derweduwe, M., Vleeschouwer, S. D., Sciot, R., Geens, W., Weng, L., Bosisio, F. M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.988872 · Cited by 56
Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade
Goswami, S., Raychaudhuri, D., Singh, P., Natarajan, S. M., Chen, Y., Poon, C. C., Hennessey, M., Tannir, A. J., Zhang, J., Anandhan, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00620-0 · Cited by 56
Yang, B., Li, X., Fu, Y., Guo, E., Ye, Y., Li, F., Liu, S., Xiao, R., Liu, C., Lu, F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2370 · Cited by 55
Self-citationPotential role of annexin A7 in cancers
Guo, C., Liu, S., Greenaway, F. T., & Sun, M. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.04.018 · Cited by 55
Construction and validation of a cuproptosis-related prognostic model for glioblastoma
Zhang, B., Xie, L., Liu, J., Liu, A., & He, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1082974 · Cited by 55
Dmello, C., Zhao, J., Chen, L., Gould, A., Castro, B. A., Arrieta, V. A., Zhang, D. Y., Kim, K.-S., Kanojia, D., Zhang, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36878-2 · Cited by 55
Self-citationHan, M., Wang, S., Zhao, W., Ni, S., Yang, N., Kong, Y., Huang, B., Chen, A., Li, X., Wang, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.002 · Cited by 54
Lee, Y., Seo, H. W., Baek, J.-H., Lim, S. H., Hwang, S., & Kim, E. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-68473-6 · Cited by 54
Zottel, A., Šamec, N., Kump, A., Dall’Olio, L. R., Dominkuš, P. P., Romih, R., Hudoklin, S., Mlakar, J., Nikitin, D. M., Sorokin, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228491 · Cited by 54
Zhang, H., Wang, Y., Zhao, Y., Liu, T., Wang, Z., Zhang, N., Dai, Z., Wu, W., Cao, H., Feng, S., et al. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13913 · Cited by 54
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy
Wei, H., Xiang, L., Wayne, A. S., Chertov, O., FitzGerald, D. J., Bera, T. K., & Pastan, I. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204523109 · Cited by 53
Evans, S. M., Putt, M. E., Yang, X.-Y., Lustig, R. A., Martinez‐Lage, M., Williams, D., Desai, A. S., Wolf, R. L., Brem, S. S., & Koch, C. J. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2051-3 · Cited by 53
Sielska, M., Przanowski, P., Pasierbińska, M., Wojnicki, K., Poleszak, K., Wojtaś, B., Grzeganek, D., Ellert‐Miklaszewska, A., Ku, M., Kettenmann, H., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0862-2 · Cited by 53
Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development
Han, L., Wang, K., Xiong, Y., Zhou, L., Yang, Y., Chen, S., Xu, P., Zhou, Y., Mao, R., Lv, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.773264 · Cited by 53
Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy
Kamran, N., Chandran, M., Lowenstein, P. R., & Castro, M. G. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.10.008 · Cited by 52
Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth
Achyut, B. R., Angara, K., Jain, M., Borin, T. F., Rashid, M. H., Iskander, A., Ara, R., Kolhe, R. B., Howard, S., Venugopal, N., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14079-4 · Cited by 52
Glioblastoma Multiforme—A Look at the Past and a Glance at the Future
King, J. L., & Benhabbour, S. R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071053 · Cited by 52
miR-25 promotes glioblastoma cell proliferation and invasion by directly targeting NEFL
Peng, G., Yuan, X., Yuan, J., Liu, Q., Dai, M., Shen, C., Jian-rong, M., Liao, Y., & Jiang, W. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2516-x · Cited by 51
Tumor Vaccines for Malignant Gliomas
Srinivasan, V. M., Ferguson, S. D., Lee, S., Weathers, S.-P. S., Kerrigan, B. C. P., & Heimberger, A. B. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0522-2 · Cited by 51
Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling
Wang, G., Shen, J., Sun, J., Jiang, Z., Fan, J., Wang, H., Yu, S., Yu, L., Liu, Y., Bao, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0774 · Cited by 51
Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma
Cho, H. J., Zhao, J., Jung, S. W., Ladewig, E., Kong, D., Suh, Y., Lee, Y., Kim, D., Ahn, S. H., Bordyuh, M., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy123 · Cited by 51
Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells
Hasan, M. N., Luo, L., Ding, D., Song, S., Bhuiyan, M. I. H., Liu, R., Foley, L. M., Guan, X., Kohanbash, G., Hitchens, T. K., et al. (2020) · Theranostics · doi:10.7150/thno.50150 · Cited by 51
GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway
Yu, X., Jin, J., Zheng, Y., Zhu, H., Xu, H., Ma, J., Lan, Q., Zhuang, Z., Chen, C. C., & Li, M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03492-3 · Cited by 51
Hippo Pathway in Regulating Drug Resistance of Glioblastoma
Casati, G., Giunti, L., Iorio, A. L., Marturano, A., Galli, L., & Sardi, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413431 · Cited by 51
Chronotherapy in Glioblastoma: state of the art and future perspectives
Petković, M., Henis, M., Heese, O., & Relógio, A. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104470 · Cited by 51
Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma
du Chatinier, A., Meel, M. H., Das, A. I., Metselaar, D. S., Waranecki, P., Bugiani, M., Breur, M., Simonds, E. F., Lu, E. D., Weiss, W. A., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac079 · Cited by 50
CXCR4 expression is associated with proneural‐to‐mesenchymal transition in glioblastoma
Khan, A. W., Lee, S., Harmancı, A. S., Patel, R., Latha, K., Yang, Y., Marisetty, A., Lee, H. K., Heimberger, A. B., Fuller, G. N., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34329 · Cited by 50
Hashimoto, A., Gao, C., Mastio, J., Kossenkov, A. V., Abrams, S. I., Purandare, A. V., Desilva, H., Wee, S., Hunt, J., Jure‐Kunkel, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1229 · Cited by 49
Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells
Tumino, N., Fiore, P. F., Pelosi, A., Moretta, L., & Vacca, P. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101668 · Cited by 49
Zhang, Y., Zhang, B., Lv, C., Zhang, N., Xing, K., Wang, Z., Lv, R., Yu, M., Xu, C., & Wang, Y. (2023) · Theranostics · doi:10.7150/thno.81407 · Cited by 49
Models of HCMV latency and reactivation
Streblow, D. N., & Nelson, J. A. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00149-5 · Cited by 48
Clark, P. A., Gaal, J. T., Strebe, J. K., Pasch, C. A., Deming, D. A., Kuo, J. S., & Robins, H. I. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.10.042 · Cited by 48
ETV2 mediates endothelial transdifferentiation of glioblastoma
Zhao, C., Gomez, G. A., Zhao, Y., Yang, Y., Cao, D., Lu, J. N., Yang, H., & Lin, S. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0007-8 · Cited by 48
Self-citationEZH2 Phosphorylation Promotes Self-Renewal of Glioma Stem-Like Cells Through NF-κB Methylation
Liu, H., Sun, Y., Qi, X., Gordon, R. E., O'Brien, J. A., Yuan, H., Zhang, J., Wang, Z., Zhang, M., Song, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00641 · Cited by 48
Liu, T., Wang, Z., Ye, L., Duan, Y., Jiang, H., He, H., Xiao, L., Wu, Q., Xia, Y., Yang, M., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01061-0 · Cited by 48
Dong, Y., Han, Q., Zou, Y., et al. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1401-0 · Cited by 47
Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
Stavrakaki, Ε., Dirven, C. M. F., & Lamfers, M. L. M. (2021) · Cancers · doi:10.3390/cancers13040614 · Cited by 47
Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
Parakh, S., Nicolazzo, J. A., Scott, A. M., & Gan, H. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.718590 · Cited by 47
Oncogenic activity of SOX1 in glioblastoma
García, I., Aldaregia, J., Marjanović, J., Aldaz, P., Moreno‐Cugnon, L., Torres-Bayona, S., Carrasco‐García, E., Garros-Regulez, L., Egaña, L., Rubio, Á., et al. (2017) · Scientific Reports · doi:10.1038/srep46575 · Cited by 46
Targeting the perivascular niche in brain tumors
Seano, G. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000417 · Cited by 46
Chandramohan, V., Bao, X., Yu, X., Parker, S., McDowall, C., Yu, Y.-R. A., Healy, P. N., Desjardins, A., Gunn, M. D., Gromeier, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0614-0 · Cited by 46
Mohapatra, S. R., Sadik, A., Tykocinski, L., Dietze, J., Poschet, G., Heiland, I., & Opitz, C. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02762 · Cited by 46
Khan, A. N. H., Emmons, T. R., Wong, J. T., Alqassim, E., Singel, K. L., Mark, J., Smith, B. E., Tario, J. D., Eng, K. H., Moysich, K. B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0556 · Cited by 46
Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus
Farrera-Sal, M., Moya-Borrego, L., Bazán‐Peregrino, M., & Alemany, R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1565 · Cited by 46
Auzmendi-Iriarte, J., Otaegi-Ugartemendia, M., Carrasco‐García, E., Azkargorta, M., Diaz, A., Saenz-Antoñanzas, A., Andermatten, J. A., García-Puga, M., Garcia, I., Elua-Pinin, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2161 · Cited by 46
Gusyatiner, O., Bady, P., Pham, M. D. T., Lei, Y. Y., Park, J., Daniel, R. T., Delorenzi, M., & Hegi, M. E. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab115 · Cited by 45
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin
Yu, S., Ren, X., & Li, L. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00296-9 · Cited by 45
Ferreira, N. N., Granja, S., Boni, F. I., Ferreira, L. M. B., Reis, R. M., Baltazar, F., & Gremião, M. P. D. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00713-8 · Cited by 44
Stewart, T. J., Liewehr, D. J., Steinberg, S. M., Greeneltch, K. M., & Abrams, S. I. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804132 · Cited by 43
The dual role of p62 in ferroptosis of glioblastoma according to p53 status
Yuan, F., Sun, Q., Zhang, S., Ye, L., Xu, Y., Deng, G., Xu, Z., Zhang, S., Liu, B., & Chen, Q. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00764-z · Cited by 43
To Detach, Migrate, Adhere, and Metastasize: CD97/ADGRE5 in Cancer
Aust, G., Zheng, L., & Quaas, M. (2022) · Cells · doi:10.3390/cells11091538 · Cited by 43
Shi, Y. Q., Ou, L., Han, S., Li, M., Peña, M. M. O., Peña, E. A., Liu, C., Nagarkatti, M., Fan, D., & Ai, W. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.44 · Cited by 42
Self-citationAlmairac, F., Turchi, L., Sakakini, N., Debruyne, D. N., Elkeurti, S., Gjernes, E., Polo, B., Bianchini, L., Fontaine, D., Paquis, P., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-0855 · Cited by 42
Effects of glioblastoma-derived extracellular vesicles on the functions of immune cells
Musatova, O. E., & Rubtsov, Y. P. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1060000 · Cited by 42
Ito, H., Watari, K., Shibata, T., Miyamoto, T., Murakami, Y., Nakahara, Y., Izumi, H., Wakimoto, H., Kuwano, M., Abé, T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0438 · Cited by 41
Hsu, J. B., Lee, G. A., Chang, T., Huang, S.-W., Le, N. Q. K., Chen, Y.-C., Kuo, D.-P., Li, Y.-T., & Chen, C. (2020) · Cancers · doi:10.3390/cancers12103039 · Cited by 41
Zhou, H., Jiang, M., Yuan, H., Ni, W., & Tai, G. (2020) · Oncology Letters · doi:10.3892/ol.2020.12410 · Cited by 41
Hansen, L. J., Yang, R., Roso, K., Wang, W., Chen, L., Yang, Q., Pirozzi, C. J., & He, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-07697-0 · Cited by 41
Tu, Z., Ouyang, Q., Long, X., Wu, L., Li, J., Zhu, X., & Huang, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837512 · Cited by 41
Li, B., Zhang, S., Huang, N., Chen, H., Wang, P., Yang, J. J., & Li, Z. (2018) · Oncology Reports · doi:10.3892/or.2018.6809 · Cited by 40
A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
Dhar, S., Gadd, S., Patel, P. A., Vaynshteyn, J., Raju, G. P., Hashizume, R., Brat, D. J., & Becher, O. J. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01336-5 · Cited by 40
G9a promotes immune suppression by targeting the Fbxw7/Notch pathway in glioma stem cells
Cao, Y., Liu, B., Cai, L., Li, Y., Huang, Y., Zhou, Y., Sun, X., Yang, W., & Sun, T. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14191 · Cited by 40
Dufrusine, B., Capone, E., Ponziani, S., Lattanzio, R., Lanuti, P., Giansanti, F., Laurenzi, V. D., Iacobelli, S., Ippoliti, R., Mangiola, A., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13453 · Cited by 40
Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
Lerner, R. G., Grossauer, S., Kadkhodaei, B., Meyers, I., Sidorov, M. K., Koeck, K., Hashizume, R., Ozawa, T., Phillips, J. J., Berger, M. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3689 · Cited by 39
Exploring the Oncogenic Role of the Tumor “Suppressor” Oncostatin M (OSM)
Chen, M., Ren, R., Lin, W., Xiang, L., Zhao, Z., & Shao, B. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02260-9 · Cited by 39
Zhu, L., Liu, J., Qiu, M.-J., Chen, J., Liang, Q. D., Peng, G., & Zou, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121711 · Cited by 39
Cytoplasmic TRADD Confers a Worse Prognosis in Glioblastoma
Chakraborty, S., Li, L., Tang, H., Xie, Y., Puliyappadamba, V. T., Raisanen, J. M., Burma, S., Boothman, D. A., Cochran, B., Wu, J. K., et al. (2013) · Neoplasia · doi:10.1593/neo.13608 · Cited by 38
Rimkus, T. K., Carpenter, R. L., Sirkisoon, S. R., Zhu, D., Pasche, B., Chan, M. D., Lesser, G. J., Tatter, S. B., Watabe, K., Debinski, W., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2933 · Cited by 38
Otvos, B., Alban, T. J., Grabowski, M. M., Bayık, D., Mulkearns-Hubert, E. E., Radivoyevitch, T., Rabljenovic, A., Johnson, S., Androjna, C., Mohammadi, A. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3262 · Cited by 38
A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1
Libby, C. J., Sajina, G. C., Benavides, G. A., Fisher, J. L., Williford, S. E., Zhang, S., Tran, A. N., Gordon, E. R., Jones, A. B., Tuy, K., et al. (2021) · Cell Adhesion & Migration · doi:10.1080/19336918.2021.1903684 · Cited by 38
Xia, L., Liu, J., Zheng, Z., Chen, Y.-J., Ding, J., Hu, Y.-H., Hu, G.-S., Xia, N., & Liu, W. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.019 · Cited by 38
Epigenetic biomarkers of T-cells in human glioma
Wiencke, J. K., Accomando, W. P., Zheng, S., Patoka, J., Dou, X., Phillips, J. J., Hsuang, G., Christensen, B. C., Houseman, E. A., Koestler, D. C., et al. (2012) · Epigenetics · doi:10.4161/epi.22675 · Cited by 37
Bernhart, E. M., Damm, S., Heffeter, P., Wintersperger, A., Asslaber, M., Frank, S., Hammer, A., Strohmaier, H. M., DeVaney, T. T. J., Mrfka, M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not303 · Cited by 37
USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1
Li, G. L., Yang, T., Chen, Y., Bao, J., Wu, D., Hu, X., Feng, C., Xu, L., Li, M., Li, G., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720307 · Cited by 37
Zhou, Y., Xiao, D., Jiang, X., & Nie, C. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03883-4 · Cited by 37
Francisco, M. A., Wanggou, S., Fan, J. J., Dong, W., Chen, X., Momin, A., Abeysundara, N., Min, H.-K., Chan, J., McAdam, R. F., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190971 · Cited by 36
T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields
Diamant, G., Simchony, H., Gasri-Plotnitsky, L., Roitman, M., Shiloach, T., Levin, A. G., Eshhar, Z., Haim, O., Pencovich, N., Grossman, R., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100100 · Cited by 36
Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
Bayık, D., Bartels, C. F., Lovrenert, K., Watson, D. C., Zhang, D., Kay, K. E., Lee, J., Lauko, A. J., Johnson, S., Lo, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3840 · Cited by 36
Self-citationLiu, L., Zhou, X., Cheng, S., Ge, Y., Chen, B., Shi, J., Li, H., Li, S., Li, Y., Yuan, J., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14031 · Cited by 36
Parker, S., McDowall, C., Sanchez-Perez, L. A., Osorio, C., Duncker, P. C., Briley, A., Swartz, A. M., Herndon, J. E., Yu, Y.-R. A., McLendon, R. E., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn5649 · Cited by 36
Linares, C. A., Varghese, A., Ghose, A., Shinde, S. D., Adeleke, S. M., Sanchez, E., Sheriff, M., Chargari, C., Rassy, E., & Boussios, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713215 · Cited by 36
Valencia, J. C., Erwin-Cohen, R. A., Clavijo, P. E., Allen, C., Sanford, M. E., Day, C.-P., Hess, M. M., Johnson, M., Yin, J., Fenimore, J. M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1148 · Cited by 35
Belotti, Y., Tolomeo, S., Yu, R., Lim, W., & Lim, C. T. (2022) · Cancers · doi:10.3390/cancers14102544 · Cited by 35
Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
Li, G., Zhang, Z., Cai, L., Tang, X., Huang, J., Yu, L., Wang, G., Zhong, K., Cao, Y. L., Liu, C., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1983306 · Cited by 34
Self-citationPorret, E., Kereselidze, D., Dauba, A., Schweitzer-Chaput, A., Jegot, B., Selingue, E., Tournier, N., Larrat, B., Novell, A., & Truillet, C. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.12.006 · Cited by 34
Biological effects of selective COX-2 inhibitor NS398 on human glioblastoma cell lines
Palumbo, P., Lombardi, F., Augello, F. R., Giusti, I., Dolo, V., Leocata, P., Cifone, M. G., & Cinque, B. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01250-7 · Cited by 33
Ramaiah, M. J., Kurappalli, R. K., Ramalingam, P. S., & Moparthi, N. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120024 · Cited by 33
Rana, R., Chauhan, K., Gautam, P., Kulkarni, M. J., Banarjee, R., Chugh, P., Chhabra, S. S., Acharya, R., Kalra, S. K., Gupta, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.778754 · Cited by 33
Jung, M. K., Aibaidula, A., Brown, D. A., Himes, B. T., Garcia, L. M. C., & Parney, I. F. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac017 · Cited by 33
Irshad, K., Srivastava, C., Malik, N., Arora, M., Gupta, Y., Goswami, S., Sarkar, C., Suri, V. S., Mahajan, S., Gupta, D. K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.813888 · Cited by 33
Dong, W., Fekete, Á., Chen, X. F., Liu, H., Beilhartz, G. L., Chen, X., Bahrampour, S., Xiong, Y., Yang, Q., Zhao, H., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00626-8 · Cited by 33
IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma
Chen, X., Liu, J., Li, Y., Zeng, Y., Wang, F., Cheng, Z., Duan, H., Pan, G., Yang, S., Chen, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42545-3 · Cited by 33
Vaccination strategies for neuro-oncology: Table 1.
Sampson, J. H., & Mitchell, D. A. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov159 · Cited by 32
Sceneay, J., Griessinger, C. M., Hoffmann, S. H. L., Wen, S., Wong, C. S. F., Krumeich, S., Kneilling, M., Pichler, B. J., & Möller, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196040 · Cited by 32
Identification of potential biomarkers and candidate small molecule drugs in glioblastoma
Lu, W., Xie, H., Yuan, C., Li, J.-J., Li, Z., & Wu, A. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01515-1 · Cited by 32
Guha, P., Gardell, J., Rabinowitz, B. A., Lopes, M. C., DaSilva, N. A., Rowley, D. C., & Katz, S. C. (2020) · Oncogene · doi:10.1038/s41388-020-01559-7 · Cited by 32
Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity
Pituch, K. C., Ζαννίκου, Μ., Ilut, L., Xiao, T., Chastkofsky, M. I., SUKHANOVA, M. J., Bertolino, N., Procissi, D., Amidei, C., Horbinski, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015800118 · Cited by 32
A chemical biology approach reveals a dependency of glioblastoma on biotin distribution
Yoon, J., Grinchuk, O. V., Kannan, S., Ang, M. J. Y., Li, Z., Tay, E. X. Y., Lok, K. Z., Lee, B. W. L., Chuah, Y. H., Chia, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf6033 · Cited by 31
Self-citationChen, R., Chen, C., Han, N., Guo, W., Deng, H., Wang, Y., Ding, Y., & Zhang, M. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17458 · Cited by 31
Saidi, D., Cheray, M., Osman, A. M., Stratoulias, V., Lindberg, O. R., Shen, X., Blomgren, K., & Joseph, B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1382790 · Cited by 30
Ravn-Boess, N., Roy, N., Hattori, T., Bready, D., Donaldson, H., Lawson, C., Lapierre, C., Korman, A., Rodrick, T. C., Liu, E., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113374 · Cited by 30
Mitochondrial enzyme GLUD2 plays a critical role in glioblastoma progression
Franceschi, S., Corsinovi, D., Lessi, F., Tantillo, E., Aretini, P., Menicagli, M., Scopelliti, C., Civita, P., Pasqualetti, F., Naccarato, A. G., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.008 · Cited by 29
Lu, Q., Ding, Y., Yang, L., & Lu, Q. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.44906 · Cited by 29
Checkpoint: Inspecting the barriers in glioblastoma immunotherapies
Preddy, I., Nandoliya, K. R., Miska, J. M., & Ahmed, A. U. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.012 · Cited by 29
Xu, S., Luo, C., Chen, D., Tang, L., Cheng, Q., Chen, L., & Liu, Z. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02642-z · Cited by 29
Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis
Glover, A. W., Zhang, Z., & Shannon-Lowe, C. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161848 · Cited by 29
Ma, Q., Shilkrut, M., Zhao, Z., Li, M., Batty, N., & Barber, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4051-0 · Cited by 28
Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies
Ratnam, N. M., Sonnemann, H. M., Frederico, S. C., Chen, H. A., Hutchinson, M.-K. N. D., Dowdy, T., Reid, C. M., Jung, J., Zhang, W., Song, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719091 · Cited by 28
Role of AHR in the control of GBM-associated myeloid cells
Gabriely, G., & Quintana, F. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.014 · Cited by 27
Gallitto, M., He, R. C., Inocencio, J. F., Wang, H., Zhang, Y., Deikus, G. Y., Wasserman, I., Strahl, M., Smith, M. L., Sebra, R., et al. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03461-4 · Cited by 27
Yang, J., & Yang, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.615976 · Cited by 27
Xiong, W., Li, C., Wan, B., Zheng, Z., Zhang, Y., Wang, S., & Fan, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.819080 · Cited by 27
Nakazawa, T., Morimoto, T., Maeoka, R., Matsuda, R., Nakamura, M., Nishimura, F., Ouji, N., Yamada, S., Nakagawa, I., Park, Y.-S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02770-6 · Cited by 27
Hazane‐Puch, F., Arnaud, J., Trocmé, C., Faure, P., Laporte, F., & Champelovier, P. (2016) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150819095426 · Cited by 26
Clavreul, A., Etcheverry, A., Tétaud, C., Rousseau, A., Avril, T., Henry, C., Mosser, J., & Meneï, P. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1683-z · Cited by 25
Jang, B., & Kim, I. A. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.440 · Cited by 25
Yeo, A. T., Shah, R., Aliazis, K., Pal, R., Xu, T., Zhang, P., Rawal, S., Rose, C. M., Varn, F. S., Appleman, V. A., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0655 · Cited by 25
Advancing Antibody Drug Conjugation
Okeley, N. M., Alley, S. C., & Senter, P. D. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.10.009 · Cited by 24
SAHA-based novel HDAC inhibitor design by core hopping method
Zang, L., Wang, X., Li, X., Wang, S., Xu, W., Xian-bin, X., Cheng, X., Ma, H., & Wang, R. (2014) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2014.08.005 · Cited by 24
Wu, S., Calero‐Pérez, P., Villamañán, L., Arias‐Ramos, N., Pumarola, M. B., Ortega‐Martorell, S., Julià‐Sapé, M., Arús, C., & Candiota, A. P. (2020) · NMR in Biomedicine · doi:10.1002/nbm.4229 · Cited by 24
Huang, N., Chen, Z., Yang, X., Gao, Y., Zhong, J., Li, Y., Xiao, F., Wang, X., Shi, Y., & Zhang, N. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad099 · Cited by 24
Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma
Moyes, K. W., Davis, A. D., Hoglund, V. J., Haberthur, K., Lieberman, N. A. P., Kreuser, S. A., Deutsch, G. H., Franco, S., Locke, D., Carleton, M. O., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1507668 · Cited by 23
Wang, Z., Gao, L., Guo, X., Lian, W., Deng, K., & Xing, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576996 · Cited by 23
Connections between Metabolism and Epigenetic Modification in MDSCs
Dai, H., Xu, H., Wang, S., & Ma, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197356 · Cited by 23
The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia
Arrieta, V. A., Najem, H., Petrosyan, E., Lee-Chang, C., Chen, P., Sonabend, A. M., & Heimberger, A. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413382 · Cited by 23
Magri, S., Musca, B., Bonaudo, C., Tushe, A., Russo, M. G., Masetto, E., Zagonel, V., Lombardi, G., Puppa, A. D., & Mandruzzato, S. (2021) · Cancers · doi:10.3390/cancers13246178 · Cited by 23
Wu, P., Guo, Y., Xiao, L., Yuan, J., Tang, C., Dong, J., & Qian, Z. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03395-6 · Cited by 23
Caruso, J. P., Koch, B. J., Benson, P. D., Varughese, E., Monterey, M. D., Lee, A. E., Dave, A. M., Kiousis, S., Sloan, A. E., & Mathupala, S. P. (2017) · Neoplasia · doi:10.1016/j.neo.2016.12.011 · Cited by 22
B4GALT3 promotes cell proliferation and invasion in glioblastoma
Wu, T., Li, Y., & Chen, B. (2020) · Neurological Research · doi:10.1080/01616412.2020.1740465 · Cited by 22
Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice
Chuntova, P., Hou, Y., Naka, R., Yamamichi, A., Chen, T., Goretsky, Y. E., Hatae, R., Nejo, T., Kohanbash, G., Mende, A., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab182 · Cited by 22
Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward
Gatto, L., Nunno, V. D., Franceschi, E., & Brandes, A. A. (2021) · Immunotherapy · doi:10.2217/imt-2021-0054 · Cited by 21
IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma
Xu, C., Bai, Y. Y., An, Z., Hu, Y., Zhang, C., & Zhong, X. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.002 · Cited by 21
Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma
Minami, N., Hong, D., Stevers, N. O., Barger, C. J., Radoul, M., Hong, C., Chen, L., Kim, Y., Batsios, G., Gillespie, A. M., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac112 · Cited by 21
Genetics and Epigenetics of Glioblastoma: Therapeutic Challenges
Zayeri, Z. D., Rasras, S., Zibara, K., & Vosughi, T. (2018) · Clinical Cancer Investigation Journal · doi:10.4103/ccij.ccij_82_17 · Cited by 20
A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR
Al-Mayhani, T. M. F., Heywood, R. M., Vemireddy, V., Lathia, J. D., Piccirillo, S. G. M., & Watts, C. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy204 · Cited by 20
Primary glioblastoma transcriptome data analysis for screening survival‐related genes
Yang, Y., Yan, R., Zhang, L., Meng, X., & Sun, W. C. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29425 · Cited by 20
Bai, K., Zhang, Y., Li, X., Tian, X., Pan, M.-M., Wang, D., & Dai, Y. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.09.021 · Cited by 20
Cheng, S., Liu, L., Wang, D., Li, Y., Li, S., Yuan, J., Huang, S., Xu, Z., Jia, B., Li, Z., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14213 · Cited by 20
Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity
Nehama, D., Woodell, A. S., Maingi, S. M., Hingtgen, S., & Dotti, G. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad092 · Cited by 20
Sun, J., Patel, C. B., Jang, T., Merchant, M. J., Chen, C., Kazerounian, S., Diers, A. R., Kiebish, M. A., Vishnudas, V. K., Gesta, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70969-0 · Cited by 19
Bazedoxifene inhibits sustained STAT3 activation and increases survival in GBM
Wightman, S. M., Alban, T. J., Chen, X., Lathia, J. D., Wang, Y., & Stark, G. R. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101192 · Cited by 19
Krishna, A. V. S. S., Ramu, A., Hariharan, S., Sinha, S., & Donakonda, S. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107433 · Cited by 19
Hijacking Sexual Immuno-Privilege in GBM—An Immuno-Evasion Strategy
Sharpe, M. A., Baskin, D. S., Jenson, A. V., & Baskin, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010983 · Cited by 18
Richard, S. A. (2020) · Disease Markers · doi:10.1155/2020/8844313 · Cited by 17
Bam, M., Chintala, S., Fetcko, K., Williamsen, B. C., Siraj, S., Liu, S., Wan, J., Xuei, X., Liu, Y., Leibold, A. T., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27955 · Cited by 17
SLC12A5 as a novel potential biomarker of glioblastoma multiforme
Chen, J., Handong, W., Deng, C., & Fei, M. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08371-y · Cited by 17
Bradykinin B1 Receptor Affects Tumor-Associated Macrophage Activity and Glioblastoma Progression
Shen, C., Huang, B., Charoensaensuk, V., Yang, L., Tsai, C., Liu, Y.-S., Lu, D., Yeh, W., & Lin, C. (2023) · Antioxidants · doi:10.3390/antiox12081533 · Cited by 17
Pucci, S., Bolchi, C., Bavo, F., Pallavicini, M., Palma, C. D., Renzi, M., Fucile, S., Benfante, R., Lascio, S. D., Lattuada, D., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105959 · Cited by 16
LXR Agonism Depletes MDSCs to Promote Antitumor Immunity
(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2018-010 · Cited by 16
Wu, X., Wan, Q., Wang, J., Hou, P., Zhang, Q., Wang, Q., & Lu, X. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s349078 · Cited by 16
An Immune-Related Gene Pairs Signature for Predicting Survival in Glioblastoma
Wang, S., & Xu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.564960 · Cited by 14
Feng, S., Liang, X., Li, J., Wang, Z., Zhang, H., Dai, Z., Luo, P., Liu, Z., Zhang, J., Xiao, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992855 · Cited by 14
Hetze, S., Barthel, L., Lückemann, L., Günther, H. S., Wülfing, C., Salem, Y., Jakobs, M., Hörbelt, T., Petschulat, J., Bendix, I., et al. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.09.006 · Cited by 13
Taghipour, M., Omidvar, A., Razmkhah, M., Ghaderi, A. A., & Mojtahedi, Z. (2017) · PubMed Central · doi:10.22074/cellj.2016.4179 · Cited by 12
Ferreira, W. A. S., Vitiello, G. A. F., Medina, T. D. S., & de Oliveira, E. H. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-10114-1 · Cited by 12
Naqvi, A. A. T., Jairajpuri, D. S., Hussain, A., Hasan, G. M., Alajmi, M. F., & Hassan, M. I. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1738959 · Cited by 11
Himes, B. T., Fain, C. E., Tritz, Z. P., Nesvick, C. L., Jin‐Lee, H. J., Geiger, P. A., Peterson, T. E., Jung, M.-Y., & Parney, I. F. (2022) · Journal of neurosurgery · doi:10.3171/2022.6.jns2274 · Cited by 11
FOXM1 maintains fatty acid homoeostasis through the SET7-H3K4me1-FASN axis
Li, X., Su, W., Wu, H., Xu, J., Tang, H., Chen, X., Yin, Z., Zhang, C., Yang, J., Yang, Y., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01540-9 · Cited by 11
Raghavan, J. V., Ganesh, R. A., Sonpatki, P., Naik, D., John, A. E., Arunachalam, P., Shah, D., S., H. P., Lakshmikantha, A., Pillai, S. V., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1957215 · Cited by 10
Yang, F., Gao, Z., Xu, J., Wang, H., Guo, Q., Xue, H., Zhao, R., Guo, X. H., & Li, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986615 · Cited by 9
Distinct Myeloid Derived Suppressor Cell Populations Promote Tumor Aggression in GlioblastomaPreprint
Jackson, C., Cherry, C., Bom, S., Dykema, A. G., Thompson, E. A., Zheng, M., Ji, Z., Hou, W., Li, R., Zhang, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.26.534192 · Cited by 9
Turchi, L., Sakakini, N., Saviane, G., Polo, B., Saurty-Seerunghen, M. S., Gabut, M., Augé‐Gouillou, C., Guerlais, V., Pasquier, C., Vignais, M., et al. (2023) · Cancers · doi:10.3390/cancers15205038 · Cited by 9
Anticancer Properties of Curcumin and Interactions With the Circadian Timing System
De, A., Beligala, D. H., Birkholz, T. M., & Geusz, M. E. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419889154 · Cited by 8
‘Slicing’ glioblastoma drivers with the Swiss cheese model
Pumar, O. T., Lathia, J. D., Watson, D. C., & Bayık, D. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.08.002 · Cited by 8
Ma, S., Guo, Z., Wang, B., Yang, M., Yuan, X., Ji, B., Wu, Y., & Chen, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.832627 · Cited by 7
Prognostic value of an APOBEC3 deletion polymorphism for glioma patients in Taiwan
Chen, C., Wei, K., Liao, W., Lin, Y., Chen, H.-C., Feng, L.-Y., Liu, C., Huang, C.-Y., Chen, K., Wu, C., et al. (2022) · Journal of neurosurgery · doi:10.3171/2022.7.jns2250 · Cited by 6
Self-citationKałuzińska‐Kołat, Ż., Kośla, K., Kołat, D., Płuciennik, E., & Bednarek, A. K. (2023) · Biology · doi:10.3390/biology12030465 · Cited by 6
Prognostic significance of TMEM131L in glioma and establishment of oxidative stress prognostic model
Li, S., Zhu, X., Qiu, H., Zuo, E., & Cheng, X. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1162394 · Cited by 5
Cited by
From Biomarkers to Behavior: Mapping the Neuroimmune Web of Pain, Mood, and Memory
Tanaka, M., & Battaglia, S. (2025) · Biomedicines · doi:10.3390/biomedicines13092226 · Cited by 13
Metadata
- Authors
- Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y.
- Venue
- Journal of Hematology & Oncology
- Published
- 2024-05-08
- Volume
- 17
- Issue
- 1
- Pages
- 31-31
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W4396735748
- Cited by
- 392
- References
- 784
- FWCI
- 91.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.